Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4445356 | 0.75 | MAPT (0.37) | GAAMAPT | |
| SCHEMBL4860322 | 0.69 | GAA (0.42) | GAAMAPT | |
| SCHEMBL4814065 | 0.66 | LTB4R (0.46) | GAAMAPT | |
| SCHEMBL23374860 | 0.64 | ACHE (0.36) | MAPT | |
| SCHEMBL14007698 | 0.58 | PRCP (0.44) | GAAMAPT | |
| SCHEMBL12837999 | 0.58 | CREBBP (0.55) | GAAMAPT | |
| SCHEMBL1736809 | 0.58 | CREBBP (0.55) | GAAMAPT | |
| SCHEMBL29572486 | 0.58 | CREBBP (0.55) | GAAMAPT | |
| SCHEMBL1868013 | 0.58 | CREBBP (0.55) | GAAMAPT | |
| SCHEMBL33268 | 0.58 | CREBBP (0.55) | GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293757-A1 | ABCA1 ELEVATING COMPOUNDS | ABELMAN MATTHEW | 2008-11-27 | — | — | US | disclosed |
| US-7432276-B2 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7423045-B2 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-20070191379-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070010544-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191379-A1 | ABCA1 elevating compounds | ABCD3, ABCB4, CETP | GAA 441/4885L3MBTL1 3771/4885MAPT 4361/4885 |
| US-20080293757-A1 | ABCA1 ELEVATING COMPOUNDS | ABCD3, ABCB4, CETP | GAA 441/4885L3MBTL1 3771/4885MAPT 4361/4885 |
| US-20070010544-A1 | ABCA1 elevating compounds | ABCD3, ABCB4, CETP | GAA 441/4885L3MBTL1 3771/4885MAPT 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.